Call Us: 1.800.873.5297

By

New England Compounding Center Meningitis Outbreak Update

As of October 16, 2012, the CDC is now reporting 233 cases of meningitis and 15 deaths associated with New England Compounding Center’s methylprednisolone acetate steroid injection. Tennessee remains the hardest hit state, but the numbers are climbing in Michigan, Virginia and Indiana. In addition to the Aspergillus fungus, the Exserohilum fungus has also been identified as […]

By

105 Injured, 8 Dead as Result of Contaminated Steroid Injections; Up to 13,000 At Risk

The Centers for Disease Control and Prevention (CDC) has reported an outbreak of fungal meningitis in patients who have received epidural steroid injections. So far, 105 cases of meningitis have been identified and eight people have died. Several people have suffered strokes related to the meningitis. Thousands more may be affected, as 13,000 patients may have […]

By

Roger Denton Appointed by Federal Judge Herndon to serve as Co-Lead of the Pradaxa Litigation

In an order dated September 27, 2012, Schlichter Bogard and Denton’s partner Roger Denton has been appointed to serve as the Plaintiffs’ Co-Lead Counsel for In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation (MDL 2385). The Pradaxa MDL was created by the U.S. Judicial Panel on Multidistrict Litigation on August 18, 2012. The MDL Panel […]

By

Pradaxa Orders Issued in MDL 2385

Judge David Herndon, of the Southern District of Illinois, has issued three case management orders relating to In re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation, MDL number 2385. The Initial Conference Order and Procedural Matters (CMO #1), Confidentiality Order (CMO #2), and Order Governing the Format of Production (CMO #3), were entered less than 10 […]

By

Judge Herndon Denies BIPI’s Motions to Dismiss

Defendant Boehringer Ingelheim Pharmaceutials, Inc. (“BIPI”) filed Motions to Dismiss in every case filed against the company. BIPI argued that the Plaintiffs failed to allege a cause of action in the Complaints against the company. BIPI argued in their Motions that the Pradaxa label properly warned against severe gastrointestinal bleeding, hemorrhagic stroke, and death (as […]

By

Pradaxa MDL Transferred to Judge Herndon (Southern District of Illinois)

Due to the large number of Pradaxa cases and likely hundreds more which we anticipate will be filed, a process has been established for consolidating the cases filed in the federal court system before a single judge for purposes of pre-trial discovery. Attorneys from around the country, including Schlichter Bogard and Denton’s Roger Denton, presented […]

By

VTE Risk in NuvaRing (Updated)

On May 10, 2012, the British Medical Journal published a new follow-up study by Dr. Øjvind Lidegaard entitled “Venous Thrombosis in Users of Non-Oral Hormonal Contraception: Follow-Up Study, Denmark 2001-10.” Øjvind Lidegaard et al., Venous Thrombosis in Users of Non-Oral Hormonal Contraception: Follow-Up Study, Denmark 2001-10, 344 BRIT. MED. J. 2990 (2012), available at http://www.bmj.com/highwire/filestream/583967/field_highwire_article_pdf/0.pdf. […]

By

Pradaxa Study RE-LY Not So Reliable

Recent journal articles have questioned the reliability of the Randomized Evaluation of Long-Term Anticoagulant Therapy (“RE-LY”) study, which gave dabigatran, also known as Pradaxa, its footing in the Atrial Fibrillation (“AF” or “A. Fib”) market. Coleman et al., Effect of Pharmacological Therapies for Stroke Prevention on Major Gastrointestinal Bleeding in Patients with Atrial Fibrillation, 66 […]

By

Pradaxa Cases Filed

Eight cases have been filed by individuals for personal injuries against Defendants Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim Corporation, Boehringer Ingelheim USA Corporation, and Boehringer Ingelheim Vetmedica, Inc., the manufacturers of Pradaxa. Pradaxa is a direct thrombin inhibitor that is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial […]

By

VTE Risk in NuvaRing

On May 10, 2012, the British Medical Journal published Dr. Lidegaard’s “Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10” which concludes “use of transdermal patches and vaginal rings conferred incidence rates of 9.7 and 7.8 confirmed venous thromboses per 10 000 exposure years, and relative risks of 7.9 and 6.5 compared […]

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.